Differential effects of IL-2 and IL-21 on expansion of the CD4 +CD25+Foxp3+ T regulatory cells with redundant roles in natural killer cell mediated antibody dependent cellular cytotoxicity in chronic lymphocytic leukemia

mAbs

Volumn 2, Issue 1, 2010, Pages 35-41

  Gowda, Aruna ^a   Ramanunni, Asha ^a   Cheney, Carolyn ^a   Rozewski, Darlene ^a   Kindsvogel, Wayne ^b   Lehman, Amy ^c   Jarjoura, David ^c   Caligiuri, Michael ^a   Byrd, John C ^a   Muthusamy, Natarajan ^a  

^a Division of Hematology   (United States)

^b ZYMOGENETICS INC   (United States)

^c OHIO STATE UNIVERSITY   (United States)

Author keywords

Antibody dependent cellular cytotoxicity; Chronic lymphocytic leukemia; IL 2; IL 21; Immunosuppression

Indexed keywords

INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 2; INTERLEUKIN 21; TRANSCRIPTION FACTOR FOXP3;

ARTICLE; CANCER SURVIVAL; CD4+ CD25+ T LYMPHOCYTE; CELL EXPANSION; CELL MEDIATED CYTOTOXICITY; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; DRUG EFFECT; DRUG INFUSION; HOMEOSTASIS; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; NATURAL KILLER CELL; PROTEIN EXPRESSION;

ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGENS, CD4; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SEPARATION; FLOW CYTOMETRY; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; INTERLEUKIN-2; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; INTERLEUKINS; KILLER CELLS, NATURAL; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; RECEPTORS, INTERLEUKIN-21; T-LYMPHOCYTES, REGULATORY;

EID: 77953658941     PISSN: 19420862     EISSN: None     Source Type: Journal    
DOI: 10.4161/mabs.2.1.10561     Document Type: Article

References (26)

1. Zheng Y, Rudensky AY. Foxp3 in control of the regulatory T cell lineage. Nat Immunol 2007; 8:457-62.
2. + natural regulatory T cells in dominant self-tolerance and autoimmune disease. Immunol Rev 2006; 212:8-27.
3. Beyer M, Schultze JL. Regulatory T cells in cancer. Blood 2006; 108:804-11.
4. Giannopoulos K, Schmitt M, Kowal M, Wlasiuk P, Bojarska-Junak A, Chen J, et al. Characterization of regulatory T cells in patients with B-cell chronic lymphocytic leukemia. Oncol Rep 2008; 20:677-82.
5. +CD25 hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine. Blood 2005; 106:2018-25.
6. + suppressor T cells: more questions than answers. Nat Rev Immunol 2002; 2:389-400.
7. Nelson BH. IL-2, regulatory T cells and tolerance. J Immunol 2004; 172:3983-8.
8. Leonard WJ, Spolski R. Interleukin-21: a modulator of lymphoid proliferation, apoptosis and differentiation. Nat Rev Immunol 2005; 5:688-98.
9. Leonard WJ, Zeng R, Spolski R. Interleukin 21: a cytokine/cytokine receptor system that has come of age. J Leukoc Biol 2008; 84:348-56.
10. Gowda A, Roda J, Hussain SR, Ramanunni A, Joshi T, Schmidt S, et al. IL-21 mediates apoptosis through upregulation of the BH3 family member BIM and enhances both direct and antibody-dependent cellular cytotoxicity in primary chronic lymphocytic leukemia cells in vitro. Blood 2008; 111:4723-30.
11. di Carlo E, de Totero D, Piazza T, Fabbi M, Ferrini S. Role of IL-21 in immune-regulation and tumor immunotherapy. Cancer Immunol Immunother 2007; 56:1323-34.
12. Jahrsdorfer B, Blackwell SE, Wooldridge JE, Huang J, Andreski MW, Jacobus LS, et al. B-chronic lymphocytic leukemia cells and other B cells can produce granzyme B and gain cytotoxic potential after interleukin-21-based activation. Blood 2006; 108:2712-9.
13. de Totero D, Meazza R, Zupo S, Cutrona G, Matis S, Colombo M, et al. Interleukin-21 receptor (IL-21R) is upregulated by CD40 triggering and mediates proapoptotic signals in chronic lymphocytic leukemia B cells. Blood 2006; 107:3708-15.
14. Setoguchi R, Hori S, Takahashi T, Sakaguchi S. Homeostatic maintenance of natural Foxp3(+) CD25(+) CD4(+) regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization. J Exp Med 2005; 201:723-35.
15. + T regulatory cells suppress NK cell-mediated immunotherapy of cancer. J Immunol 2006; 176:1582-7.
16. + T cell suppressor function. J Immunol 2004; 172:6519-23.
17. + T cell suppressor function. Eur J Immunol 2004; 34:366-76.
18. King C, Ilic A, Koelsch K, Sarvetnick N. Homeostatic expansion of T cells during immune insufficiency generates autoimmunity. Cell 2004; 117:265-77.
19. Kukreja A, Cost G, Marker J, Zhang C, Sun Z, Lin-Su K, et al. Multiple immuno-regulatory defects in type-1 diabetes. J Clin Invest 2002; 109:131-40.
20. Piccirillo CA, Letterio JJ, Thornton AM, McHugh RS, Mamura M, Mizuhara H, et al. CD4(+)CD25(+) regulatory T cells can mediate suppressor function in the absence of transforming growth factor beta1 production and responsiveness. J Exp Med 2002; 196:237-46.
21. Ghiringhelli F, Menard C, Martin F, Zitvogel L. The role of regulatory T cells in the control of natural killer cells: relevance during tumor progression. Immunol Rev 2006; 214:229-38.
22. + regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner. J Exp Med 2005; 202:1075-85.
23. Weiss GR, Margolin KA, Aronson FR, Sznol M, Atkins MB, Dutcher JP, et al. A randomized phase II trial of continuous infusion interleukin-2 or bolus injection interleukin-2 plus lymphokine-activated killer cells for advanced renal cell carcinoma. J Clin Oncol 1992; 10:275-81.
24. Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Dohner H, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008; 111:5446-56.
25. Becknell B, Trotta R, Yu J, Ding W, Mao HC, Hughes T, et al. Efficient infection of human natural killer cells with an EBV/retroviral hybrid vector. J Immunol Methods 2005; 296:115-23.
26. Golay J, Manganini M, Rambaldi A, Introna M. Effect of alemtuzumab on neoplastic B cells. Haematologica 2004; 89:1476-83.